Earnings call transcript: Prestige Consumer Healthcare Q1 2025 misses forecasts

Prestige Consumer Healthcare (PBH) reported Q1 2025 earnings below consensus, with EPS of $0.95 and revenue of $249.5 million missing forecasts of $1.00 and $261 million respectively, triggering a 12.75% pre-market stock decline. The revenue shortfall, down 6.6% year-over-year, was largely due to extended supply chain issues for its Clear Eyes product. Despite this, the company achieved a 6% year-over-year EPS increase, improved gross margins to 56.2%, and record free cash flow of $78 million. To mitigate supply risks, PBH announced the $100 million acquisition of its key Clear Eyes supplier, Pillar Five Pharma, and adjusted its full-year revenue and EPS guidance downwards, anticipating significant supply recovery in H2 FY26, with full normalization by FY27.

Analysis

Prestige Consumer Healthcare (PBH) reported a challenging first quarter, missing consensus on both revenue and EPS, which prompted a significant 12.75% pre-market stock decline. The top-line miss was substantial, with revenue falling 6.6% year-over-year to $249.5 million, primarily due to severe supply chain constraints for its key Clear Eyes product and volatile retail order patterns. Consequently, management has lowered its full-year guidance, now projecting an organic revenue decline of 1.5% to 3%. Despite these headwinds, the company demonstrated notable operational efficiency. EPS grew 6% year-over-year to $0.95, gross margin expanded by 150 basis points to 56.2%, and the company generated a record quarterly free cash flow of $78 million. In a decisive strategic move to address the root cause of its revenue shortfall, PBH announced the acquisition of its key supplier, Pillar Five Pharma, for approximately $100 million. This vertical integration is intended to secure long-term supply, with management anticipating a meaningful recovery in the second half of the fiscal year, although a full normalization is not expected until fiscal 2027. The company's financial health remains robust, evidenced by a strong Altman Z-Score of 9.37 and continued share repurchases.

Key Decisions for Investors

• Investors should anticipate continued share price volatility in the near term, given the significant Q1 earnings miss, downward revision of full-year guidance, and ongoing supply chain disruptions expected to impact the first half of the fiscal year.
• The sharp stock decline may present an opportunity for long-term investors to evaluate the company's strong underlying fundamentals, including record free cash flow, expanding gross margins, and the strategic acquisition of Pillar Five, which is designed to resolve a core operational bottleneck.
• It is critical to monitor the execution of the Clear Eyes supply chain recovery in the second half, as the successful integration of Pillar Five and ramp-up of new production capacity is the primary catalyst for meeting revised guidance and restoring investor confidence.
• Note management's commitment to robust capital allocation, evidenced by the $35 million share repurchase in Q1, which, combined with strong cash generation, provides a degree of fundamental support for the valuation amidst current operational challenges.